Display options
Cite
Barron TI, Sharp L, Visvanathan K. Beta-adrenergic blocking drugs in breast cancer: a perspective review. Ther Adv Med Oncol. 2012;4(3):113-25doi: 10.1177/1758834012439738.
Barron, T. I., Sharp, L., & Visvanathan, K. (2012). Beta-adrenergic blocking drugs in breast cancer: a perspective review. Therapeutic advances in medical oncology, 4(3), 113-25. https://doi.org/10.1177/1758834012439738
Barron, Thomas I, et al. "Beta-adrenergic blocking drugs in breast cancer: a perspective review." Therapeutic advances in medical oncology vol. 4,3 (2012): 113-25. doi: https://doi.org/10.1177/1758834012439738
Barron TI, Sharp L, Visvanathan K. Beta-adrenergic blocking drugs in breast cancer: a perspective review. Ther Adv Med Oncol. 2012 May;4(3):113-25. doi: 10.1177/1758834012439738. PMID: 22590485; PMCID: PMC3349076.
Copy Download .nbib Format: NLM
Share it on

Ther Adv Med Oncol. 2012 May;4(3):113-25. doi: 10.1177/1758834012439738.

Beta-adrenergic blocking drugs in breast cancer: a perspective review.

Therapeutic advances in medical oncology

Thomas I Barron, Linda Sharp, Kala Visvanathan

Affiliations

  1. Department of Pharmacology & Therapeutics, Trinity Centre for Health Sciences, St James's Hospital, Dublin 8, Ireland.

PMID: 22590485 PMCID: PMC3349076 DOI: 10.1177/1758834012439738

Abstract

The purpose of this review is to present the preclinical, epidemiological and clinical data relevant to the association between β-blockers and breast cancer progression. Preclinical studies have shown that β-adrenergic receptor (β-AR) signalling can inhibit multiple cellular processes involved in breast cancer progression and metastasis, including extracellular matrix invasion, expression of inflammatory and chemotactic cytokines, angiogenesis and tumour immune responses. This has led to the hypothesis that the commonly prescribed class of β-AR antagonist drugs (β-blockers) may favourably impact cancer progression. A number of recent pharmacoepidemiological studies have examined the association between β-blocker exposure and breast cancer progression. The results from these studies have suggested a potential role for targeting the β-AR pathway in breast cancer patients. Larger observational studies are, however, required to confirm these results. Questions regarding the type of β-blocker, predictive biomarkers or tumour characteristics, appropriate treatment paradigms and, most importantly, efficacy must also be answered in randomized clinical studies before β-blockers can be considered a therapeutic option for patients with breast cancer.

Keywords: adrenergic beta-agonists; adrenergic beta-antagonists; adrenergic receptors; breast neoplasms; neoplasms; propranolol

References

  1. Cancer Cell. 2009 Mar 3;15(3):167-70 - PubMed
  2. Cancer Biol Ther. 2010 Jul 1;10(1):19-29 - PubMed
  3. J Clin Invest. 2010 May;120(5):1515-23 - PubMed
  4. Breast Cancer Res Treat. 2011 Jan;125(2):351-62 - PubMed
  5. J Cancer Res Clin Oncol. 1990;116(3):303-6 - PubMed
  6. Breast Cancer Res Treat. 2011 Nov;130(2):457-63 - PubMed
  7. J Immunol. 2010 Mar 1;184(5):2449-57 - PubMed
  8. J Steroid Biochem Mol Biol. 1991 Mar;38(3):307-20 - PubMed
  9. Cancer. 2007 Sep 1;110(5):1130-8 - PubMed
  10. Cell Cycle. 2007 Feb 15;6(4):430-3 - PubMed
  11. J Clin Oncol. 2011 Jul 1;29(19):2645-52 - PubMed
  12. Cancer Res. 2006 Nov 1;66(21):10357-64 - PubMed
  13. Brain Behav Immun. 2009 Jan;23(1):10-5 - PubMed
  14. J Clin Oncol. 2010 Sep 10;28(26):4019-21 - PubMed
  15. Clin Cancer Res. 2006 Jan 15;12(2):369-75 - PubMed
  16. Breast. 2012 Feb;21(1):107-8 - PubMed
  17. Brain Behav Immun. 2005 Mar;19(2):114-26 - PubMed
  18. Nat Clin Pract Oncol. 2008 Aug;5(8):466-75 - PubMed
  19. Brain Behav Immun. 2009 Feb;23(2):267-75 - PubMed
  20. Nat Rev Cancer. 2006 Mar;6(3):240-8 - PubMed
  21. J Clin Oncol. 2011 Jul 1;29(19):2635-44 - PubMed
  22. Breast Cancer Res Treat. 2000 Mar;60(2):153-66 - PubMed
  23. J Cell Biochem. 2008 Sep 1;105(1):53-60 - PubMed
  24. Lancet Oncol. 2004 Apr;5(4):254-8 - PubMed
  25. J Clin Oncol. 2010 Sep 10;28(26):4094-9 - PubMed
  26. Clin Cancer Res. 2003 Oct 1;9(12):4514-21 - PubMed
  27. Cancer Res. 2001 Apr 1;61(7):2866-9 - PubMed
  28. Ann Surg Oncol. 2008 Jul;15(7):2042-52 - PubMed
  29. Breast Cancer Res Treat. 2011 Dec;130(3):747-58 - PubMed
  30. Pharmacol Res. 1996 Apr-May;33(4-5):255-60 - PubMed
  31. Nat Med. 2006 Aug;12(8):939-44 - PubMed
  32. Eur J Pharmacol. 2011 Aug 31;665(1-3):1-7 - PubMed
  33. J Clin Oncol. 2011 Jul 1;29(19):2612-6 - PubMed
  34. Clin Cancer Res. 2009 Apr 15;15(8):2695-702 - PubMed
  35. Oncogene. 2007 May 31;26(26):3777-88 - PubMed
  36. Anticancer Res. 1991 Mar-Apr;11(2):677-80 - PubMed
  37. Oncol Res. 2010;19(1):45-54 - PubMed
  38. Cardiovasc Drugs Ther. 1999 Apr;13(2):123-6 - PubMed
  39. Cancer Res. 2007 Nov 1;67(21):10389-96 - PubMed
  40. Oncotarget. 2010 Nov;1(7):628-38 - PubMed
  41. Br J Dermatol. 2010 Aug;163(2):269-74 - PubMed
  42. Breast Cancer Res Treat. 2011 Sep;129(2):549-56 - PubMed
  43. Int J Cancer. 2006 Jun 1;118(11):2744-9 - PubMed
  44. Int J Oncol. 2002 Jul;21(1):153-7 - PubMed
  45. Brain Behav Immun. 2010 Aug;24(6):952-8 - PubMed
  46. Int J Cancer. 2011 May 15;128(10):2306-16 - PubMed
  47. Br J Clin Pharmacol. 2011 Jul;72(1):157-61 - PubMed
  48. Oncol Rep. 2009 Oct;22(4):825-30 - PubMed
  49. Brain Behav Immun. 2008 Mar;22(3):318-23 - PubMed
  50. Pharmacol Res. 1992 Dec;26(4):377-84 - PubMed
  51. Breast Cancer Res Treat. 2003 Jul;80(1):63-70 - PubMed
  52. Pancreas. 2009 Jan;38(1):94-100 - PubMed
  53. J Biol Chem. 2007 May 11;282(19):14094-100 - PubMed
  54. Eur J Pediatr. 2011 Apr;170(4):493-501 - PubMed
  55. Int J Cancer. 2004 Nov 1;112(2):231-8 - PubMed
  56. Cancer Res. 2010 Sep 15;70(18):7042-52 - PubMed

Publication Types